Entries Tagged 'MedWatch' ↓

Tygacil (tigecycline): Label Change - Increased Mortality Risk

Healthcare professionals should consider alternatives to Tygacil in patients with severe infections.

Huber Needles: Recall - Risk of Coring

Risk of infection, damage or death of tissue, swelling, or other serious adverse health consequences occurring as a result of the core travelling through blood vessels into the patient’s lungs.

Fingerstick Devices to Obtain Blood Specimens: Initial Communication - Risk of Transmitting Bloodborne Pathogens

Increase in reports of bloodborne infection transmission resulting from the shared use of fingerstick and point-of-care blood testing devices.

TimeOut Capsules: Undeclared Drug Ingredient

Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil, a chemical similar to sildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

MasXtreme Capsules (Natural Wellness) - product contains undeclared drug ingredient

UPDATED 08/25/2010. Product marketed as dietary supplement contains undeclared Aminotadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

Octagam [Immune Globulin Intravenous (human)] 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events

Customers asked to immediately quarantine the use of affected lots due to the potential for serious thromboembolic events.

Mr. Magic Male Enhancer: Undeclared Drug Ingredient

Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil and sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

INOMAX DS Drug-Delivery System: Class I Recall - Risk of Interruption of Drug Flow

Potential for failure of a pressure switch, which may have an impact on the administration of INOMAX for inhalation to patients.

Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk

FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa

Midodrine hydrochloride: FDA Proposes Withdrawal of Low Blood Pressure Drug

Companies failed to provide evidence of clinical benefit of midodrine hydrochloride because required post-approval studies that verify the clinical benefit of the drug have not been done.

6 French Engage Introducer Devices by St. Jude Medical: Recall - Potential for Separation of Shaft From Hub

Potentially life threatening episode of bleeding could occur during surgical procedures.

Prolatis’: Undeclared Drug Ingredient

Product marketed as dietary supplement contains undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis

Warnings and Precautions section of Prescribing Information and patient Medication Guide revised to include information about the risk of aseptic meningitis.

Novacare LLC Products: Recall - Undeclared Drug Ingredient

Products marketed as dietary supplement sexual enhancers for men contain undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.

Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product

Suspected counterfeit product is weaker, and breaks or bends before necessary force can be applied to stop blood flow. Excessive blood loss can endanger the victim’s life and ultimately lead to death.